Revvity Inc.
$ 93.03
-0.99%
20 Apr - close price
- Market Cap 10,505,041,000 USD
- Current Price $ 93.03
- High / Low $ 93.97 / 92.44
- Stock P/E 45.61
- Book Value 64.57
- EPS 2.06
- Next Earning Report 2026-05-05
- Dividend Per Share $0.28
- Dividend Yield 0.31 %
- Next Dividend Date 2026-05-08
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 118.21
- 52 Week Low 81.19
About
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$115.13
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-02 | 2025-10-27 | 2025-07-28 | 2025-04-28 | 2025-01-31 | 2024-11-04 | 2024-07-29 | 2024-04-29 | 2024-02-01 | 2023-10-30 | 2023-08-01 | 2023-05-11 |
| Reported EPS | 0.87 | 0.4 | 1.18 | 1.01 | 1.42 | 1.28 | 1.22 | 0.98 | 1.25 | 1.18 | 1.21 | 1.01 |
| Estimated EPS | 0.85 | 0.5 | 1.14 | 0.95 | 1.38 | 1.13 | 1.12 | 0.94 | 1.16 | 1.19 | 1.19 | 1.02 |
| Surprise | 0.02 | -0.1 | 0.04 | 0.06 | 0.04 | 0.15 | 0.1 | 0.04 | 0.09 | -0.01 | 0.02 | -0.01 |
| Surprise Percentage | 2.3529% | -20% | 3.5088% | 6.3158% | 2.8986% | 13.2743% | 8.9286% | 4.2553% | 7.7586% | -0.8403% | 1.6807% | -0.9804% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.02 |
| Currency | USD |
Previous Dividend Records
| May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-08 | 2026-02-06 | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-02-07 | 2024-11-08 | 2024-08-09 | 2024-05-10 | 2024-02-09 |
| Amount | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 |
Next Dividend Records
| Dividend per share (year): | $0.28 |
| Dividend Yield | 0.31% |
| Next Dividend Date | 2026-05-08 |
| Ex-Dividend Date | 2026-04-17 |
Recent News: RVTY
2026-04-21 01:29:16
Revvity Inc. (US76155R1086) provides tools for drug discovery and diagnostics, positioning it in the life sciences sector with robust demand. The company's core business model focuses on precision tools for research and diagnostics, emphasizing recurring revenue from consumables and services. Revvity aims for long-term growth through strategic investments in high-growth areas like cell and gene therapy, digital integration, and global expansion, while facing risks from biopharma budget cuts and competitive pressure.
2026-04-20 13:56:21
Revvity, Inc. (RVTY) has filed a Form 144 notice proposing the sale of 80 common shares with an aggregate value of $7,424.00. The shares originate from an ESPP purchase on December 31, 2021, and restricted stock vesting on April 15, 2022. The filing also indicates the shares are listed on the NYSE.
2026-04-19 03:24:15
Revvity recently launched new AI-enabled oncology platform tools and molecular cloning software, Signals BioDesign, aimed at streamlining cancer and biologics research. This strategic pivot towards higher-margin software and integrated life-science tools could significantly impact its investment narrative by offsetting pressures in diagnostics and funding-sensitive research markets. While these advancements are promising, investors should also consider risks like regulatory changes in China affecting diagnostics revenue and the current premium valuation with low return on equity.
2026-04-18 05:42:20
Wall Street Zen has downgraded Revvity (NYSE:RVTY) from a "Buy" to a "Hold" rating, aligning with the broader analyst consensus. The company, which recently reported stronger-than-expected earnings and set a positive FY2026 guidance, nevertheless faces a "relatively rich valuation" with a P/E of 45.19. The average analyst rating is now "Hold" with an average price target of $110.17, despite various recent adjustments from other firms.
2026-04-17 20:38:30
Shares of Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health experienced significant gains following the reopening of the Strait of Hormuz. This event signals reduced global logistics and energy costs, particularly benefiting healthcare providers and medical device manufacturers due to lower operational and shipping expenses. The "risk-on" sentiment driven by a ceasefire has also spurred investment in high-growth biotech and pharmaceutical companies, as macroeconomic uncertainty recedes and investor confidence in long-term R&D and clinical trials increases.
2026-04-17 16:30:00
Shares of Revvity Inc. (RVTY) rose 5.03% to $93.96 on Friday, outperforming the broader stock market. This rise snapped a two-day losing streak for the company's stock. The S&P 500 Index and Dow Jones Industrial Average also saw gains during the favorable trading session.
